meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
antibody–drug conjugate
sacituzumab govitecan
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
talazoparib
versus all
vs chemotherapy
vs Standard of Care (SoC)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
sacituzumab govitecan
title
Standard of Care (SoC)
title
ASCENT (all population), 2021 NCT02574455 mBC-Triple negative (TNBC) - 2nd Line (L2) 267/262
ASCENT (patients without brain metastases), 2021 NCT02574455 mBC-Triple negative (TNBC) - 2nd Line (L2) 235/233
Pathology:
mBC-Triple negative (TNBC) - 2nd Line (L2);
mBC-Triple negative (TNBC) - 2nd Line (L2)
ASCENT (all population), 2021
ASCENT (patients without brain metastases), 2021
sacituzumab govitecan
2
T1
T1
Standard of Care (SoC)
0
T0
T0